An Open-label, Roll-over Study With Rilpivirine in Combination With a Background Regimen Containing Other Antiretrovirals (ARVs) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Who Participated in Rilpivirine Pediatric Studies
Latest Information Update: 05 May 2025
At a glance
- Drugs Rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Sponsors Janssen R&D Ireland; Janssen Sciences Ireland UC
Most Recent Events
- 27 Apr 2025 Planned End Date changed from 31 Dec 2031 to 30 Jun 2027.
- 09 Dec 2024 Planned End Date changed from 1 Dec 2031 to 31 Dec 2031.
- 09 Dec 2024 Planned primary completion date changed from 1 Jun 2027 to 30 Jun 2027.